Treatment of Light Chain Deposition Disease Using Bortezomib-Based Regimen Followed by Thalidomide-Based Regimen in a Saudi Male
نویسندگان
چکیده
منابع مشابه
Treatment of Light Chain Deposition Disease Using Bortezomib-Based Regimen Followed by Thalidomide-Based Regimen in a Saudi Male
Light chain deposition disease (LCDD) is a rare illness with, as yet, no clear evidence-based guidelines for its treatment. To the best of our knowledge, LCDD has not been previously reported from Saudi Arabia. We present in this report, a 38-year-old Saudi male who presented with clinical features suggestive of hypertensive nephropathy but kidney biopsy later revealed the diagnosis of LCDD. Hi...
متن کاملBortezomib Based Chemotherapy for Light Chain Deposition Disease.
Light chain deposition disease (LCDD) is a rare systemic disorder in which monoclonal light chains are abnormally secreted due to clonal proliferation of plasma cells and get deposited in various organs; the kidneys being the common one to be affected leading to renal failure. Advocated therapeutic options include chemotherapy with alkylating agents and steroids, High-Dose Melphalan (HDM) with ...
متن کاملComparison of the effect of levofloxacin-based three-drug regimen with clarithromycin-based four-drug regimen in the treatment of Helicobacter pylori infection in Birjand: Short Communication
Given the high prevalence of Helicobacter pylori infection in Iran, eradicating it with an effective, low-cost, and easy diet is one of the challenges ahead The aim of this study was designed to compare the effect of "levofloxacin-based regimen “with” clarithromycin-based regimen” in the treatment of Helicobacter pylori. This quasi-experimental study was performed on 161 patients with Helicobac...
متن کاملTreatment of idiopathic light chain deposition disease: complete remission with bortezomib and dexamethasone.
Light chain deposition disease (LCDD) is a rare clinical entity characterized by the deposition of light chain immunoglobulins in different tissues and primarily affects the kidneys, followed by the liver and heart. This disease often manifests as nephrotic syndrome with marked proteinuria and rapid deterioration of renal function. More than 50% of cases are secondary to multiple myeloma or oth...
متن کاملTreatment of antibody-mediated rejection in kidney transplant recipients: a single-center experience with a bortezomib-based regimen.
OBJECTIVES Antibody-mediated rejection after kidney transplant is less responsive to conventional antirejection therapies. The proteasome inhibitor bortezomib has activity against mature plasma cells that produce damaging donor-specific antibodies. We present our experience of using a bortezomib-based regimen in patients with severe antibody-mediated rejection. MATERIALS AND METHODS A retrosp...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Case Reports in Nephrology
سال: 2016
ISSN: 2090-6641,2090-665X
DOI: 10.1155/2016/7485695